A recent Phase 2b human clinical study involving Tecrea’s Nanocin technology as part of a novel topical terbinafine antifungal product, has met the primary endpoint (BBTAF202) in patients with onychomycosis, showing superiority over placebo (vehicle) with a high level of statistical significance.
The result demonstrates the clinical potential of Tecrea’s technology which is applicable to a number of other conditions where delivery to the site of drug action remains a challenge.
For more information contact info@tecrea.com